189 related articles for article (PubMed ID: 15839952)
21. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment.
Liu J; Li H; Cao S; Zhang X; Yu J; Qi J; An X; Yu W; Ren X; Hao X
J Immunother; 2014; 37(2):115-22. PubMed ID: 24509174
[TBL] [Abstract][Full Text] [Related]
22. [Neoadjuvant chemotherapy and ovarian cancer].
Ray-Coquard I; Saba C; Bachelot T; Méeus P; Mignotte H; Blondet R; Treilleux I; Peix M; Guastalla JP
Bull Cancer; 2006 Jul; 93(7):669-76. PubMed ID: 16873075
[TBL] [Abstract][Full Text] [Related]
23. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience.
Mendivil AA; Rettenmaier MA; Abaid LN; Brown JV; Mori KM; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2017 Aug; 80(2):405-410. PubMed ID: 28669065
[TBL] [Abstract][Full Text] [Related]
24. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care.
Schink JC
Semin Oncol; 1999 Feb; 26(1 Suppl 1):2-7. PubMed ID: 10071968
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
26. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
27. [Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.].
Angius G; Sepe P; Papa A; Tomao S; Tomao F
Recenti Prog Med; 2017 Jun; 108(6):269-281. PubMed ID: 28631775
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer.
Colombo N; Van Gorp T; Parma G; Amant F; Gatta G; Sessa C; Vergote I
Crit Rev Oncol Hematol; 2006 Nov; 60(2):159-79. PubMed ID: 17018256
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.
Schwartz PE; Rutherford TJ; Chambers JT; Kohorn EI; Thiel RP
Gynecol Oncol; 1999 Jan; 72(1):93-9. PubMed ID: 9889037
[TBL] [Abstract][Full Text] [Related]
30. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
[TBL] [Abstract][Full Text] [Related]
32. Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Kaklamani VG
Oncologist; 2016 Aug; 21(8):922-30. PubMed ID: 27256875
[TBL] [Abstract][Full Text] [Related]
33. Gynecologic malignancies.
Schilder RJ; Scher RM; Young RC
Cancer Chemother Biol Response Modif; 1993; 14():530-56. PubMed ID: 8312118
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Vergote IB; De Wever I; Decloedt J; Tjalma W; Van Gramberen M; van Dam P
Semin Oncol; 2000 Jun; 27(3 Suppl 7):31-6. PubMed ID: 10952124
[TBL] [Abstract][Full Text] [Related]
35. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
Lin H; Changchien CC
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
[TBL] [Abstract][Full Text] [Related]
36. [Malignant ovarian cancer: conservative treatment and quality of life in young patients].
Ivanov S
Akush Ginekol (Sofiia); 2008; 47(5):11-3. PubMed ID: 19227771
[TBL] [Abstract][Full Text] [Related]
37. Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer.
Gordinier ME; Dizon DS; Weitzen S; Disilvestro PA; Moore RG; Granai CO
J Palliat Med; 2007 Feb; 10(1):61-6. PubMed ID: 17298255
[TBL] [Abstract][Full Text] [Related]
38. Surgical cytoreduction in ovarian cancer.
McCreath WA; Chi DS
Oncology (Williston Park); 2004 May; 18(5):645-53, discussion 653-4, 656, 658. PubMed ID: 15209191
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of ovarian cancer].
Cianti C
Clin Ter; 2002; 153(2):135-44. PubMed ID: 12078339
[TBL] [Abstract][Full Text] [Related]
40. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Kurtz JE; Gebski V; Sukhin V; Carey M; Kong I; Glasspool RM; Berek JS; de Paiva Batista M; Hall M; Kim JW; Yeoshoua E; Fujiwara N; Nam BH; Polleis S; Lee JY; Strojna A; Farrelly L; Schwameis R; Fossati R; Darlington AS; Lai CH; Wright AA; Rosenblat O; Harter P; Roxburgh P; Chowdhury RR; Chang TC; Paoletti X; Friedlander M;
Gynecol Oncol; 2021 May; 161(2):502-507. PubMed ID: 33612336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
